Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Complex formulations that are difficult to replicate controlled-release systems, transdermal patches, sterile injectables can delay generic entry by 12 to 24 months beyond compound patent expiry, because generic companies need time to demonstrate bioequivalence through clinical studies
For patients who have been managing that cost out-of-pocket, the arrival of a generic represents a meaningful change
Jan 2021;38(1):101-123
Targeted supplementation cannot reverse these biological shifts and anyone who tells you otherwise isn't being straight with you
US$ 24.57
US$ 24.31
US$ 20.87
US$ 21.21
US$ 27.47
